[go: up one dir, main page]

CY1116031T1 - Aνti-ilt7 αντισωμα - Google Patents

Aνti-ilt7 αντισωμα

Info

Publication number
CY1116031T1
CY1116031T1 CY20141101048T CY141101048T CY1116031T1 CY 1116031 T1 CY1116031 T1 CY 1116031T1 CY 20141101048 T CY20141101048 T CY 20141101048T CY 141101048 T CY141101048 T CY 141101048T CY 1116031 T1 CY1116031 T1 CY 1116031T1
Authority
CY
Cyprus
Prior art keywords
ilt7
antibody
ipc
activity
inhibited
Prior art date
Application number
CY20141101048T
Other languages
English (en)
Inventor
Yumiko Kamogawa
Minkwon Cho
Naoko Arai
Koji Ishida
Original Assignee
Sbi Biotech Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sbi Biotech Co., Ltd. filed Critical Sbi Biotech Co., Ltd.
Publication of CY1116031T1 publication Critical patent/CY1116031T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/555—Interferons [IFN]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6866—Interferon

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)

Abstract

Ένα αντίσωμα που προσδένεται στο IPC αποκτήθηκε, χρησιμοποιώντας ένα ζωικό κύτταρο, στο οποίο μια πρωτεΐνη κυτταρικής μεμβράνης που μπορεί να συσχετιστεί με το ILT7 συν-εκφράστηκε ως ένα ανοσογόνο. Το αντίσωμα της εφεύρεσης έχει υψηλή ειδικότητα που επιτρέπει την ανοσολογική διάκριση μεταξύ άλλων μορίων της οικογένειας ILT και του ILT7. Το αντι-ΙLΤ7 αντίσωμα της εφεύρεσης προσδενόταν στο IPC και ανέστειλε την δραστικότητα αυτού. Με το αντι-ΙLT7 αντίσωμα της εφεύρεσης, η δραστικότητα IPC μπορεί να ανασταλεί και η σχετιζόμενη με ιντερφερόνη νόσος μπορεί να θεραπευτεί ή να προληφθεί. Η έκφραση του ILT7 διατηρείται σταθερή στο IPC ακόμα και υπό την παρουσία IFNa. Συνεπώς, μια ανασταλτική δράση της δραστικότητας IPC από το αντι-ILT7 αντίσωμα μπορεί να αναμένεται ακόμη και σε έναν ασθενή αυτοάνοσης νόσου με αυξημένη παραγωγή IFNα.
CY20141101048T 2005-12-20 2014-12-17 Aνti-ilt7 αντισωμα CY1116031T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005366465 2005-12-20
EP12168586.1A EP2532681B1 (en) 2005-12-20 2006-12-20 Anti-ILT7 antibody

Publications (1)

Publication Number Publication Date
CY1116031T1 true CY1116031T1 (el) 2017-01-25

Family

ID=38188642

Family Applications (3)

Application Number Title Priority Date Filing Date
CY20131100538T CY1114227T1 (el) 2005-12-20 2013-07-02 Αντισωμα αντι-ilt7
CY20141101048T CY1116031T1 (el) 2005-12-20 2014-12-17 Aνti-ilt7 αντισωμα
CY20181101167T CY1121294T1 (el) 2005-12-20 2018-11-07 Αντι-ilt7 αντισωμα

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20131100538T CY1114227T1 (el) 2005-12-20 2013-07-02 Αντισωμα αντι-ilt7

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20181101167T CY1121294T1 (el) 2005-12-20 2018-11-07 Αντι-ilt7 αντισωμα

Country Status (29)

Country Link
US (6) US8084585B2 (el)
EP (4) EP1964852B1 (el)
JP (2) JP5020828B2 (el)
KR (3) KR101526934B1 (el)
CN (5) CN105111311B (el)
AU (1) AU2006328470B2 (el)
BR (1) BRPI0620141B1 (el)
CA (2) CA2634116C (el)
CY (3) CY1114227T1 (el)
DK (3) DK2913343T3 (el)
ES (3) ES2526079T3 (el)
HK (1) HK1218126A1 (el)
HR (2) HRP20130494T1 (el)
HU (1) HUE039865T2 (el)
IL (1) IL192266A (el)
LT (1) LT2913343T (el)
ME (1) ME02111B (el)
MX (1) MX2008007682A (el)
NZ (3) NZ599683A (el)
PL (3) PL2913343T3 (el)
PT (3) PT2913343T (el)
RS (2) RS52860B (el)
RU (2) RU2456298C2 (el)
SG (2) SG10201602095PA (el)
SI (3) SI2532681T1 (el)
TR (1) TR201816574T4 (el)
UA (1) UA97946C2 (el)
WO (1) WO2007072866A1 (el)
ZA (1) ZA200805850B (el)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2892724B1 (fr) * 2005-11-02 2008-01-04 Lab Francais Du Fractionnement Anticorps cytotoxiques diriges contre des anticorps inhibiteurs du facteur viii.
AU2010319531A1 (en) * 2009-11-10 2012-05-24 Amgen Inc. Anti-c-MPL antibodies
US8945569B2 (en) 2009-11-19 2015-02-03 Oncomed Pharmaceuticals, Inc. Jagged-binding agents and uses thereof
MY197016A (en) 2010-02-24 2023-05-20 Immunogen Inc Folate receptor 1 antibodies and immunoconjugates and uses thereof
WO2011137114A1 (en) * 2010-04-26 2011-11-03 Abraxis Bioscience, Llc Sparc binding antibodies and uses thereof
PT2694106T (pt) 2011-04-01 2018-03-05 Immunogen Inc Métodos para aumentar eficácia de terapia de cancro de folr1
US9567391B2 (en) 2012-03-20 2017-02-14 Biogen Ma Inc. JCV neutralizing antibodies
US9567392B2 (en) 2012-03-20 2017-02-14 Biogen Ma Inc. JCV neutralizing antibodies
US9845356B2 (en) 2012-08-03 2017-12-19 Dana-Farber Cancer Institute, Inc. Single agent anti-PD-L1 and PD-L2 dual binding antibodies and methods of use
SG10201804260QA (en) 2012-08-31 2018-07-30 Immunogen Inc Diagnostic assays and kits for detection of folate receptor 1
JP2016536330A (ja) 2013-08-30 2016-11-24 イミュノジェン， インコーポレイテッド 葉酸受容体１の検出用の抗体及びアッセイ
US10035847B2 (en) 2013-10-02 2018-07-31 The Rockefeller University Amyloid protofibril antibodies and methods of use thereof
US10294301B2 (en) * 2013-12-24 2019-05-21 Astellas Pharma Inc. Anti-human BDCA-2 antibody
US20170306046A1 (en) 2014-11-12 2017-10-26 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
KR20170128256A (ko) * 2015-03-18 2017-11-22 시애틀 지네틱스, 인크. Cd48 항체 및 이의 접합체
DK3313884T3 (da) * 2015-06-29 2021-02-22 Immunogen Inc Anti-cd123-antistoffer og konjugater og derivater deraf
WO2017049149A1 (en) 2015-09-17 2017-03-23 Immunogen, Inc. Therapeutic combinations comprising anti-folr1 immunoconjugates
CN108463248B (zh) 2015-11-12 2022-10-21 西雅图基因公司 聚糖相互作用化合物及使用方法
BR112018010279A2 (pt) * 2015-11-19 2019-02-05 Abbvie Stemcentrx Llc novos anticorpos anti-emr2 e métodos de uso
WO2017130060A1 (en) 2016-01-26 2017-08-03 Ciriello Christopher John Automated dental treatment system
US20190031780A1 (en) * 2016-01-27 2019-01-31 Siamab Therapeutics, Inc. Compositions and methods for targeting cancer stem cells
WO2017149538A1 (en) 2016-03-01 2017-09-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Antibodies specific to human poliovirus receptor (pvr)
EP3426298A4 (en) * 2016-03-10 2019-11-27 Viela Bio, Inc. ILT7-BINDING MOLECULES AND METHOD OF USE THEREOF
SG11201808525UA (en) 2016-04-04 2018-10-30 Bioverativ Usa Inc Anti-complement factor bb antibodies and uses thereof
CA3054939A1 (en) 2017-03-03 2018-09-07 Seattle Genetics, Inc. Glycan-interacting compounds and methods of use
AU2018323955A1 (en) 2017-08-30 2020-03-19 Phanes Therapeutics, Inc. Anti-LAG-3 antibodies and uses thereof
WO2019075220A1 (en) 2017-10-11 2019-04-18 Bioverativ Usa Inc. METHODS FOR INDUCING COMPLEMENT ACTIVITY
TWI816715B (zh) 2017-11-17 2023-10-01 美商默沙東有限責任公司 對免疫球蛋白樣轉錄本3(ilt3)具特異性之抗體及其用途
KR20200103751A (ko) * 2017-12-20 2020-09-02 라디뮨 테라퓨틱스 인코포레이티드 센트린-1에 대한 항체, 이의 제조 방법, 및 용도
WO2019141092A1 (zh) * 2018-01-18 2019-07-25 四川科伦博泰生物医药股份有限公司 抗lag-3抗体及其用途
US20200017596A1 (en) * 2018-05-10 2020-01-16 Abvision, Inc. Monoclonal antibodies activating cd40 and uses thereof
CN116650149A (zh) 2018-05-10 2023-08-29 网络牙科(美国)公司 自动牙钻
MX2022001841A (es) 2019-08-12 2022-08-17 Biond Biologics Ltd Anticuerpos contra ilt2 y uso de los mismos.
CN115135337A (zh) * 2019-12-06 2022-09-30 维埃拉生物股份有限公司 使用ilt7结合蛋白的治疗方法
JP7794758B2 (ja) 2020-04-20 2026-01-06 ジェンザイム・コーポレーション ヒト化抗補体Ｂｂ因子抗体およびその使用
CN116801810A (zh) 2020-09-03 2023-09-22 网络牙科(美国)公司 用于牙齿解剖结构的cna分析的方法和装置
JP2024516698A (ja) * 2021-05-04 2024-04-16 ビエラ バイオ インコーポレイテッド Ｉｌｔ７結合タンパク質を使用する、自己免疫疾患の治療方法
CA3261409A1 (en) 2022-07-27 2024-02-01 Viela Bio, Inc. FORMULATIONS CONTAINING AN IMMUNOGLOBULIN 7-TYPE TRANSCRIPT-BINDING PROTEIN (ILT7)
CN115819604B (zh) * 2022-09-09 2025-04-15 季华实验室 抗双链dna抗体、核苷酸片段、磁珠及提取外周血游离dna的方法
WO2024188356A1 (en) * 2023-03-16 2024-09-19 Inmagene Biopharmaceuticals (Hangzhou) Co., Ltd. Ilt7-targeting antibodies and uses thereof
CN116948032B (zh) * 2023-09-19 2023-12-12 汇智生物技术(苏州)有限公司 人源cd4单克隆抗体及其制备方法和应用
CN120098124A (zh) * 2023-12-05 2025-06-06 苏州普乐康医药科技有限公司 一种抗bdca-2抗体及其制备方法和应用
WO2026002175A1 (zh) * 2024-06-27 2026-01-02 无锡徕特康生物科技有限公司 靶向ilt7和cd89的髓细胞衔接子抗体及其用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA952797B (en) * 1994-04-12 1996-10-07 Res Dev Foundation Method of treating auto-immune diseases using type one interferons
US6107090A (en) * 1996-05-06 2000-08-22 Cornell Research Foundation, Inc. Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains
ATE412433T1 (de) * 1999-02-12 2008-11-15 Scripps Research Inst Methoden zur behandlung von tumoren und metastasen unter verwendung einer anti-angiogenen und immun-therapien
AU2001236807A1 (en) * 2000-02-10 2001-08-20 Abbott Laboratories Antibodies that bind human interleukin-18 and methods of making and using
US6897067B2 (en) * 2000-11-03 2005-05-24 Regents Of The University Of Michigan Surface transfection and expression procedure
US20030148316A1 (en) 2001-08-01 2003-08-07 Lipford Grayson B. Methods and compositions relating to plasmacytoid dendritic cells
JP4384492B2 (ja) * 2001-10-13 2009-12-16 アステリオン・リミテッド グリコシルホスファチジルイノシトール含有ポリペプチド
CA2484000A1 (en) * 2002-05-24 2003-12-04 Schering Corporation Neutralizing human anti-igfr antibody
AU2003252328A1 (en) 2002-08-01 2004-02-23 Ginkgo Biomedical Research Institute Co., Ltd. Method of detecting mouse interferon-producing cells
WO2004023973A2 (en) * 2002-09-12 2004-03-25 Incyte Corporation Molecules for diagnostics and therapeutics
EP1664762A4 (en) 2003-09-03 2008-08-13 Us Gov Health & Human Serv METHOD OF IDENTIFYING AND DIAGNOSIS OF, AND VIEWING, SURVIVAL IN LYMPHOMA
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound

Also Published As

Publication number Publication date
CN110776566A (zh) 2020-02-11
AU2006328470A1 (en) 2007-06-28
JPWO2007072866A1 (ja) 2009-06-04
HRP20141226T1 (hr) 2015-02-27
CN110776566B (zh) 2025-07-15
US20160130343A1 (en) 2016-05-12
JP2012143232A (ja) 2012-08-02
EP1964852A1 (en) 2008-09-03
EP2913343B1 (en) 2018-08-08
US20200339682A1 (en) 2020-10-29
IL192266A (en) 2014-09-30
NZ616992A (en) 2015-07-31
HRP20130494T1 (en) 2013-08-31
AU2006328470A2 (en) 2008-10-09
KR101526934B1 (ko) 2015-06-26
EP1964852A4 (en) 2010-02-24
PT1964852E (pt) 2013-07-10
KR101585532B1 (ko) 2016-01-14
CN101379089B (zh) 2013-08-07
ME02111B (me) 2015-10-20
CN103360492A (zh) 2013-10-23
PL1964852T3 (pl) 2013-09-30
SI2913343T1 (sl) 2019-01-31
PT2532681E (pt) 2014-12-23
CY1121294T1 (el) 2020-05-29
RS52860B (sr) 2013-12-31
KR20140053232A (ko) 2014-05-07
PL2532681T3 (pl) 2015-03-31
RU2599450C2 (ru) 2016-10-10
HK1218126A1 (zh) 2017-02-03
US20170204179A1 (en) 2017-07-20
CA2994756C (en) 2020-10-27
US8084585B2 (en) 2011-12-27
US8470992B2 (en) 2013-06-25
UA97946C2 (ru) 2012-04-10
DK1964852T3 (da) 2013-07-08
CN105111311B (zh) 2019-10-18
US20090280128A1 (en) 2009-11-12
SI2532681T1 (sl) 2015-03-31
PT2913343T (pt) 2018-11-21
CN101379089A (zh) 2009-03-04
SG170749A1 (en) 2011-05-30
DK2532681T3 (en) 2015-01-05
KR101624587B1 (ko) 2016-05-26
US20120135003A1 (en) 2012-05-31
HK1179638A1 (en) 2013-10-04
BRPI0620141A2 (pt) 2011-11-01
ES2699428T3 (es) 2019-02-11
RU2008129715A (ru) 2010-01-27
RU2012112046A (ru) 2013-10-10
RU2456298C2 (ru) 2012-07-20
EP2913343A1 (en) 2015-09-02
NZ599683A (en) 2013-11-29
EP1964852B1 (en) 2013-04-17
PL2913343T3 (pl) 2019-03-29
CN105111311A (zh) 2015-12-02
KR20080090430A (ko) 2008-10-08
IL192266A0 (en) 2008-12-29
DK2913343T3 (en) 2018-11-26
HUE039865T2 (hu) 2019-02-28
NZ569910A (en) 2012-06-29
SI1964852T1 (sl) 2013-09-30
JP5020828B2 (ja) 2012-09-05
CA2634116C (en) 2018-03-27
ES2526079T3 (es) 2015-01-05
BRPI0620141B1 (pt) 2024-04-30
JP5420688B2 (ja) 2014-02-19
RS53752B1 (sr) 2015-06-30
HK1214603A1 (en) 2016-07-29
SG10201602095PA (en) 2016-05-30
CA2994756A1 (en) 2007-06-28
EP3441403A1 (en) 2019-02-13
MX2008007682A (es) 2008-10-23
HK1124347A1 (en) 2009-07-10
EP2532681B1 (en) 2014-10-01
CA2634116A1 (en) 2007-06-28
ES2416716T3 (es) 2013-08-02
US20130259872A1 (en) 2013-10-03
TR201816574T4 (tr) 2018-11-21
KR20150031485A (ko) 2015-03-24
AU2006328470B2 (en) 2012-08-16
LT2913343T (lt) 2018-11-26
WO2007072866A1 (ja) 2007-06-28
CY1114227T1 (el) 2016-08-31
CN120718150A (zh) 2025-09-30
ZA200805850B (en) 2009-04-29
EP2532681A1 (en) 2012-12-12

Similar Documents

Publication Publication Date Title
CY1116031T1 (el) Aνti-ilt7 αντισωμα
NO20091064L (no) Antistoffer mot IL-17A
CY1124819T1 (el) Ανθρωπινα αντισωματα αντι- fel d1 και μεθοδοι χρησης αυτων
CY1121672T1 (el) Αντισωματα που προσδενουν τα il-17a και il-17f
CY1123518T1 (el) Ανθρωπινα αντισωματα enanti-tau
CY1116488T1 (el) Αντισωματα anti-προπερδινης
CY1119751T1 (el) Υλικα και μεθοδοι για θεραπεια ή προληψη ασθενειων που σχετιζονται me her-3
CY1121536T1 (el) Ανθρωπινα αντισωματα εναντι-αλφα-συνουκλεϊνης
CR9253A (es) Fijacion de la dosificacion de anticuerpos her
CY1118880T1 (el) Ανθρωπινα anti-il-23 αντισωματα, συνθεσεις, μεθοδοι και χρησεις
CY1118447T1 (el) Fc ΜΕΤΑΛΛΑΓΜΑΤΑ ΑΝΤΙΣΩΜΑΤΩΝ ΜΕ ΑΦΑΙΡΕΘΕΙΣΕΣ ΤΕΛΕΣΤΙΚΕΣ ΛΕΙΤΟΥΡΓΙΕΣ
CY1121072T1 (el) Αντισωματα αντι-ρ-σελεκτινης και μεθοδοι χρησης αυτων στην αντιμετωπιση φλεγμονωδων νοσων
EA200970954A1 (ru) Пентаспецифические антитела, способы их получения и применения
CY1119722T1 (el) Δημιουργια και περιγραφη πληρως ανθρωπινων θεραπευτικων αντισωματων λαμβανομενων μεσω hucal gold ειδικων για ανθρωπινό cd38
CY1112288T1 (el) Θεραπεια του καρκινου με αντισωματα κατα της il-1a
NO20090069L (no) Malrettede forbindelser rettet mot binding til PDGFR-alfa og deres anvendelse
CY1110895T1 (el) Περιοχες συνθετικης ανοσοσφαιρινης με ιδιοτητες δεσμευσης τροποποιημενες σε περιοχες του μοριου διαφορετικες απο τις περιοχες προσδιορισμου συμπληρωματικοτητας
CY1118053T1 (el) Φαρμακευτικες συνθεσεις με ανθεκτικοτητα σε διαλυτο cea
UA106194C2 (ru) Диагностика и лечение рака с применением антитела к ereg
MX2010004251A (es) Anticuerpo anti-bst2.
ATE553778T1 (de) Für humanes hepcidin spezifische antikörper
CY1120803T1 (el) Πρωτεϊνες δεσμευσης με αντιγονο ειδικες για το συστατικο ρ αμυλοειδους ορου
ES2570731T3 (es) Método de detección de cáncer
AR069290A1 (es) Anticuerpos monoclonales que se unen al hgm -csf (factor estimulante de la colonia de granulocitos-macrofagos) y las composiciones medicas que los comprenden
NI201100064A (es) Anticuerpos humanos de la alta afinidad para el receptor il-4 humano fundamento.